À retenir
Among 4044 older adults in the English Longitudinal Study of Ageing, 376 had sarcopenia at baseline, and they had a much higher chance of poor quality of life at 10 years (odds ratio 5.82, 95% CI 3.45-9.82). It is an observational link, and the 5.82 is an odds ratio, not a risk multiplier.
Study design
Étude de cohorte
Reading basis
Published abstract
Reading focus
Association & confounding
Cette explication éditoriale existe en anglais, chinois simplifié et chinois traditionnel. Cette interface affiche la lecture en anglais.
Question de recherche
Studies of sarcopenia and quality of life disagree, and most are cross-sectional or in clinical populations. The authors tested whether having sarcopenia at baseline predicts quality of life 10 years later in a large representative sample of older English adults.
Population et méthode
Cohort study using the English Longitudinal Study of Ageing, with 4044 participants at baseline (mean age 70.7 years; 55.1% female). Sarcopenia was defined as low handgrip strength plus low skeletal muscle mass index. Quality of life was measured with CASP-19 (control, autonomy, self-realisation and pleasure; higher is better). Multivariable logistic regression tested poor quality of life at follow-up, and a generalized linear model with repeated measures estimated mean score changes, matching for baseline quality of life and adjusting for confounders.
Résultats
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1376 of 4044 participants had sarcopenia at baseline.
- 2After adjusting for confounders, sarcopenia was associated with higher odds of poor quality of life at follow-up (OR 5.82, 95% CI 3.45-9.82).
- 3After matching for baseline quality of life and adjusting for confounders, people with sarcopenia scored lower on CASP-19 (mean difference −3.94, 95% CI −4.77 to −3.10).
Limites et incertitude
- 1Observational, so confounding by other illnesses or frailty not captured by the adjustments is possible, and the title's causal wording goes beyond the design.
- 2Sarcopenia was assessed once at baseline, and people may have recovered or worsened over 10 years.
- 3The abstract does not say how many people were lost to follow-up, how poor quality of life was defined, or whether the CASP-19 difference is meaningful in practice.
- 4Only 376 had sarcopenia, so the very large odds ratio has a wide interval; this reading is based on the abstract only.
Mise en perspective
Low muscle strength and mass in later life goes along with a worse quality of life years later. It is a reason to take muscle health seriously, not proof that treating sarcopenia will restore quality of life. Anyone worried about weakness should talk to their clinician.
Vos données
Handgrip strength and body composition are not captured by most wearables. Daily steps, chair-stand ability and training logs of resistance sessions are practical stand-ins to follow over months, using the same device and conditions.
Comprendre ce type de preuve
Exposure precedes follow-up outcomes, but confounding and reverse causation can remain. A hazard ratio is not an individual absolute risk or a demonstrated intervention effect.
Résumé structuré des auteurs English
Le résumé original en anglais est reproduit avec attribution sous la licence ouverte indiquée. Il s’agit d’une source, pas d’une interprétation MoveVitals. L’analyse préparée figure ci-dessus ; vérifiez les conclusions importantes dans la source.
Purpose
Mixed findings exist for sarcopenia/quality of life (QoL) relationship. Moreover, the majority of studies in this area have utilized a cross-sectional design or specific clinical populations. Therefore, the aim of the present study was to examine the association between sarcopenia at baseline and QoL at 10 years follow-up in a large representative sample of older English adults.
Methods
Sarcopenia was diagnosed as having low handgrip strength and low skeletal muscle mass index. QoL was measured using the CASP (control, autonomy, self-realisation and pleasure)-19, with higher values reflecting higher QoL. Multivariable logistic regression analysis was conducted to assess prospective associations between sarcopenia at baseline and poor QoL at follow-up; generalized linear model with repeated measures was used for reporting mean changes during follow-up between sarcopenia and not.
Results
Among 4044 older participants initially included at baseline (mean age: 70.7 years; 55.1% females), 376 had sarcopenia. In the multivariable analysis, after adjusting for several potential confounders, sarcopenia at baseline was associated with a higher incidence of poor QoL (odds ratio, OR = 5.82; 95% confidence interval, CI 3.45-9.82). After matching for QoL values at baseline and adjusting for potential confounders, people with sarcopenia reported significantly lower values in CASP-19 (mean difference = - 3.94; 95% CI - 4.77 to - 3.10).
Conclusions
In this large representative sample of older English adults, it was observed that sarcopenia at baseline was associated with worse scores of QoL at follow-up compared to those without sarcopenia at baseline. It may be prudent to target those with sarcopenia to improve QoL.
Sources et attribution
Sarcopenia reduces quality of life in the long-term: longitudinal analyses from the English longitudinal study of ageing.
Veronese N, Koyanagi A, Cereda E, Maggi S, Barbagallo M, Dominguez LJ, Smith L.
European geriatric medicine · 2022-02-25
DOI: 10.1007/s41999-022-00627-3 ↗PubMed · 35212911 ↗Europe PMC · Licence indiquée: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
Interprétation éditoriale MoveVitals · contenu éducatif · aucune évaluation clinique individuelle enregistrée
Sources vérifiées 2026-11-01
Guides pratiques
À lire ensemble
ACSM review of 137 reviews: resistance training works, and few programme details matter
The American College of Sports Medicine pooled 137 systematic reviews (over 30,000 healthy adults) and concluded that resistance training beats no exercise for strength, muscle size, power, endurance and several function tests. Few programme details changed results consistently: heavier loads (80% or more of one-repetition maximum) and 2 to 3 sets favoured strength, and at least 10 sets a week favoured muscle size, while training to failure, exercise type and periodization did not. It summarises reviews rather than new trials, gives no pooled effect sizes, and drew mostly on untrained adults and overlapping source trials.
Medicine & Science in Sports & Exercise
Nearly every resistance training plan beat no exercise; heavy loads led for strength
In a network meta-analysis of randomised trials in healthy adults (178 studies and 5097 people for strength, 119 studies and 3364 people for muscle size), nearly all resistance training prescriptions beat no exercise. Higher-load, multiset, thrice-weekly training ranked best for strength (standardised mean difference 1.60, 95% credible interval 1.38 to 1.82) and higher-load, multiset, twice-weekly training for muscle size (0.66, 0.47 to 0.85). Most prescriptions could not be statistically separated from each other (the 95% interval contained zero in 91% of the comparisons between them) and risk of bias was moderate to high, so the rankings are tentative.
British Journal of Sports Medicine
Muscle-strengthening linked to lower risk of death, heart disease, cancer and diabetes
Pooling 16 prospective cohort studies of adults, people who did muscle-strengthening activity had a 15% lower risk of all-cause mortality (RR 0.85, 95% CI 0.79 to 0.93) and a 17% lower risk of both cardiovascular disease and diabetes (RR 0.83 for each) than people who did none. The pooled mortality curve was lowest at about 40 min/week (RR 0.83), but whether larger amounts help or hurt is unclear. All of this is observational, from mostly US self-reported data, and the authors rated the certainty of evidence as very low for most outcomes.
British Journal of Sports Medicine
Protein supplements and weight training: small extra gains, smaller in older adults
Pooling 49 randomised trials with 1,863 healthy adults who did resistance training for at least 6 weeks, protein supplements added 0.30 kg of fat-free mass (95% CI 0.09 to 0.52) and 2.49 kg of one-repetition-maximum strength (0.64 to 4.33) on top of training alone. These gains were small next to the effect of training itself, were weaker with older age, and the suggested plateau near 1.6 g/kg/day was not statistically significant (p=0.079). One author has received funding from the US National Dairy Council, which supported trials in the analysis.
British Journal of Sports Medicine

